ESPR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ESPR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Esperion Therapeutics's book value per share for the quarter that ended in Mar. 2024 was $-1.57.
During the past 3 years, the average Book Value Per Share Growth Rate was -1.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Esperion Therapeutics was 28.00% per year. The lowest was -58.50% per year. And the median was -3.20% per year.
Esperion Therapeutics's current price is $2.21. Its book value per share for the quarter that ended in Mar. 2024 was $-1.57. Hence, today's PB Ratio of Esperion Therapeutics is .
During the past 13 years, the highest P/B Ratio of Esperion Therapeutics was 109.07. The lowest was 6.29. And the median was 15.39.
The historical data trend for Esperion Therapeutics's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Esperion Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Book Value per Share | Get a 7-Day Free Trial | 0.73 | -3.71 | -3.24 | -4.34 | -3.85 |
Esperion Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Book Value per Share | Get a 7-Day Free Trial | -3.78 | -3.69 | -3.66 | -3.85 | -1.57 |
For the Drug Manufacturers - Specialty & Generic subindustry, Esperion Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Esperion Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Esperion Therapeutics's PB Ratio falls into.
Esperion Therapeutics's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:
Book Value Per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (-455.0 | - | 0.0) | / | 118.2 | |
= | -3.85 |
Esperion Therapeutics's Book Value Per Share for the quarter that ended in Mar. 2024 is calculated as:
Book Value Per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (-294.3 | - | 0.0) | / | 187.9 | |
= | -1.57 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Esperion Therapeutics (NAS:ESPR) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Thank you for viewing the detailed overview of Esperion Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Eric Warren | officer: Chief Commercial Officer | 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108 |
J Martin Carroll | director | C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873 |
Stephen Rocamboli | director | C/OPARMOUNT CAPITAL, 787 SEVENTH AVE 48TH FL, NEW YORK NY 10019 |
Sheldon L. Koenig | officer: Chief Operating Officer | C/O PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Joanne M. Foody | officer: Chief Medical Officer | C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108 |
Benjamin Looker | officer: General Counsel | C/O TRILLIUM THERAPEUTICS INC., 2488 DUNWIN DRIVE, MISSISSAUGA A6 L5L 1J9 |
Benjamin Halladay | officer: Chief Financial Officer | ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108 |
Fischer Seth H.z. | director | C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121 |
Biotech Target N V | 10 percent owner | ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000 |
Alan Fuhrman | director | C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121 |
Timothy M Mayleben | director, officer: Pres & Chief Executive Officer | 3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108 |
Ashley Hall | officer: Chief Development Officer | C/O ESPERION THERAPEUTICS INC., 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI 48108 |
Tracy M Woody | director | 2656 CROSSPARK ROAD, SUITE 100, CORALVILLE IA 52241 |
Richard Bartram | officer: Chief Financial Officer | C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108 |
Nicole Vitullo | director, 10 percent owner | 3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121 |
From GuruFocus
By sperokesalga sperokesalga • 06-01-2023
By Marketwired • 06-28-2023
By Marketwired • 07-17-2023
By Marketwired • 08-08-2023
By sperokesalga sperokesalga • 05-09-2023
By Marketwired • 08-01-2023
By Marketwired • 10-31-2023
By GlobeNewswire • 11-11-2023
By GlobeNewswire • 01-19-2024
By sperokesalga sperokesalga • 05-04-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.